Synaptogenix, Inc. (SNPX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the potential breakthroughs in treating neurodegenerative diseases? Synaptogenix, Inc. (SNPX), a clinical-stage biopharmaceutical company founded in 2012, is at the forefront, leveraging Bryostatin-1 to develop targeted therapeutics. With a focus on conditions like Alzheimer's, Fragile X Syndrome, and stroke, how does Synaptogenix aim to restore cognitive function and regenerate cerebral connections? Join us as we delve into the history, ownership, mission, operational mechanisms, and revenue generation strategies of Synaptogenix, a company with a $3.17 million market capitalization as of today.

Synaptogenix, Inc. (SNPX) History

Synaptogenix, Inc. Founding Timeline

Year established

Synaptogenix, Inc. was established in 2003.

Original location

The company is located in Rockville, Maryland.

Founding team members

The key people include:

• Dr. Alan Tuchman: CEO and Chairman
• Daniel Chain: Principal Financial Officer

Initial capital/funding

Information regarding the initial capital and funding is not available in the provided search results.

Synaptogenix, Inc. Evolution Milestones

Synaptogenix, Inc. Transformative Moments

• 2012: Positive Phase 2a Trial Results: The Phase 2a trial results of Bryostatin-1 marked a significant turning point, showcasing statistically significant cognitive improvement in patients with moderately severe Alzheimer's disease. This provided initial validation of their approach and spurred further development efforts.
• 2018: Orphan Drug Designation: Receiving Orphan Drug Designation for Bryostatin-1 in treating Fragile X Syndrome provided key incentives, including market exclusivity and potential for accelerated regulatory pathways, highlighting the drug's potential in addressing rare diseases.
• 2021: Publication in the Journal of Alzheimer's Disease: The peer-reviewed publication reinforced the clinical promise of Bryostatin-1, demonstrating statistically significant improvement in patients with advanced Alzheimer’s disease, thereby bolstering investor confidence and attracting further research interest.
• 2023: Exclusive License Agreement: Entering into an exclusive license agreement with the University of California, Riverside expanded the company's intellectual property portfolio, adding novel compounds targeting neurodegenerative diseases and diversifying their therapeutic pipeline.
• 2024: FDA Clearance of IND application: FDA clearance of the IND application for Bryostatin-1 in advanced Alzheimer’s Disease allowed Synaptogenix to proceed with a Phase 2b clinical trial, a critical step towards potential market approval and commercialization.

To gain more insights into the company and its investors, check this out: Exploring Synaptogenix, Inc. (SNPX) Investor Profile: Who’s Buying and Why?

Synaptogenix, Inc. (SNPX) Ownership Structure

Understanding Synaptogenix, Inc.'s ownership structure provides valuable insights into its control and governance. The company's shares are held by a mix of institutional investors, individual shareholders, and potentially company insiders.

Synaptogenix, Inc. Current Status

Synaptogenix, Inc. is a public company, trading on the stock market under the ticker symbol SNPX.

Synaptogenix, Inc. Ownership Breakdown

The ownership of Synaptogenix, Inc. is distributed among various types of shareholders. The following table provides an overview of the ownership breakdown:

Synaptogenix, Inc. Leadership

The leadership team of Synaptogenix, Inc. is responsible for the strategic direction and operational management of the company. As of April 2025, key members of the leadership team include:

• Alan Tuchman, M.D.: Chief Executive Officer and President
• Stephen M. Barr: Chief Financial Officer

For more in-depth information on Synaptogenix, Inc. and its investors, check out this resource: Exploring Synaptogenix, Inc. (SNPX) Investor Profile: Who’s Buying and Why?

Synaptogenix, Inc. (SNPX) Mission and Values

Synaptogenix, Inc. focuses on developing therapeutics for neurodegenerative diseases, aiming to address significant unmet medical needs. The company is dedicated to improving patient outcomes through innovative research and development.

Synaptogenix's Core Purpose

Official mission statement

Synaptogenix's mission is centered on pioneering innovative treatments for neurodegenerative diseases, with a focus on Alzheimer's disease. The company aims to develop and commercialize novel therapies that can slow, halt, or reverse the progression of these debilitating conditions, ultimately improving the quality of life for patients and their families.

• Developing innovative treatments for neurodegenerative diseases.
• Focusing on Alzheimer's disease and related disorders.
• Improving the quality of life for patients and their families.

Vision statement

Synaptogenix envisions a future where neurodegenerative diseases are no longer a major threat to public health. The company strives to be a leader in the development of disease-modifying therapies that can transform the lives of individuals affected by these conditions. Synaptogenix aims to create a world where people can maintain their cognitive function and independence as they age.

• Leading the development of disease-modifying therapies.
• Transforming the lives of individuals affected by neurodegenerative diseases.
• Creating a world where people can maintain cognitive function and independence.

Company slogan/tagline

While Synaptogenix does not have a specific, publicly advertised slogan or tagline, their work and communications reflect a commitment to innovation and hope in the fight against neurodegenerative diseases.

• Commitment to innovation in neurodegenerative disease treatment.
• Focus on hope for patients and families affected by these conditions.
• Dedication to scientific advancement and therapeutic breakthroughs.

To delve deeper into the company's mission and vision, explore: Mission Statement, Vision, & Core Values of Synaptogenix, Inc. (SNPX).

Synaptogenix, Inc. (SNPX) How It Works

Synaptogenix, Inc. is a biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, particularly Alzheimer's disease, by targeting the underlying mechanisms of synaptic dysfunction.

Synaptogenix, Inc.'s Product/Service Portfolio

Synaptogenix, Inc.'s Operational Framework

Synaptogenix operates primarily as a research and development company, advancing its lead drug candidate, Bryostatin-1, through clinical trials. The company's operational framework involves:

• Drug Development: Focusing on Bryostatin-1, a molecule with the potential to treat Alzheimer's disease and other cognitive impairments.
• Clinical Trials: Conducting Phase 2 clinical trials to evaluate the safety and efficacy of Bryostatin-1 in Alzheimer's patients.
• Partnerships: Collaborating with research institutions and other pharmaceutical companies to expand research efforts and potential applications of Bryostatin-1.
• Intellectual Property: Securing and maintaining patents related to Bryostatin-1 and its uses.
• Fundraising: Raising capital through public offerings and other financing activities to fund ongoing research and development. For instance, in 2024, Synaptogenix announced a $6.2 million private placement.

To gain more insights into the company's investor profile, you can explore: Exploring Synaptogenix, Inc. (SNPX) Investor Profile: Who’s Buying and Why?

Synaptogenix, Inc.'s Strategic Advantages

Synaptogenix's strategic advantages include:

• Novel Approach: Targeting synaptogenesis, a unique approach to treating Alzheimer's disease compared to other treatments that primarily focus on amyloid plaques.
• Orphan Drug Designation: Bryostatin-1 has received orphan drug designation from the FDA for the treatment of Fragile X Syndrome, providing potential market exclusivity and other benefits.
• Clinical Data: Positive signals from Phase 2 clinical trials suggest potential efficacy in improving cognitive function in Alzheimer's patients.
• Experienced Team: A management team with experience in drug development and commercialization.
• Strategic Collaborations: Partnerships with leading research institutions enhance the company's scientific expertise and development capabilities.

Synaptogenix, Inc. (SNPX) How It Makes Money

Synaptogenix, Inc. primarily generates revenue through the clinical development and potential commercialization of its lead drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease and other neurodegenerative disorders.

Synaptogenix, Inc.'s Revenue Breakdown

As a clinical-stage biopharmaceutical company, Synaptogenix, Inc. currently does not have products on the market and therefore generates minimal revenue. Its primary source of funding comes from:

Synaptogenix, Inc.'s Business Economics

Synaptogenix, Inc.'s business economics are characterized by high research and development (R&D) costs and a long lead time to potential revenue generation. Key aspects include:

• Drug Development Costs: Significant investment is required to fund clinical trials, regulatory submissions, and manufacturing process development.
• Intellectual Property: Patents and proprietary technology are crucial for maintaining a competitive edge and securing future revenue streams.
• Partnerships and Licensing: Strategic alliances with larger pharmaceutical companies can provide funding and expertise, potentially leading to future royalty payments.
• Market Opportunity: The large and growing market for Alzheimer's disease treatments presents a substantial revenue opportunity if Bryostatin-1 is successfully commercialized.

Synaptogenix, Inc.'s Financial Performance

Synaptogenix, Inc.'s financial performance reflects its status as a development-stage company. Key points include:

• R&D Expenses: A significant portion of operating expenses is allocated to clinical trials and research activities. For instance, the company's focus remains heavily invested in advancing Bryostatin-1 through clinical trials.
• Cash Burn Rate: Monitoring the rate at which the company spends its cash reserves is critical, as it indicates the runway available to fund operations until potential revenue generation.
• Funding Activities: The company relies on equity financing, grants, and potential partnerships to fund its operations.
• Net Losses: As is typical for biotech companies in the development phase, Synaptogenix, Inc. experiences net losses as it invests heavily in R&D without generating product revenue.

To gain a deeper understanding of Synaptogenix, Inc.'s financial health, explore this insightful analysis: Breaking Down Synaptogenix, Inc. (SNPX) Financial Health: Key Insights for Investors

Synaptogenix, Inc. (SNPX) Market Position & Future Outlook

Synaptogenix, Inc. is a biopharmaceutical company focusing on developing therapies for neurodegenerative diseases, particularly Alzheimer's disease; its future hinges significantly on the success of its lead drug candidate, Bryostatin-1.

Competitive Landscape

Opportunities & Challenges

Industry Position

Synaptogenix, Inc. holds a unique position in the Alzheimer's disease treatment landscape due to its focus on synaptic regeneration, differentiating it from companies primarily targeting amyloid plaques. Here are some key points regarding their industry position:

• Novel Approach: Unlike many competitors focusing on amyloid plaque removal, Synaptogenix targets synaptic growth and regeneration.
• Clinical Stage: As of April 2025, the company's future heavily relies on the clinical trial outcomes of Bryostatin-1.
• Market Niche: If approved, Bryostatin-1 could potentially address a segment of the Alzheimer's market not fully served by existing treatments.

For more insights into the company's core values and strategic vision, explore: Mission Statement, Vision, & Core Values of Synaptogenix, Inc. (SNPX).